hematologic malignancies
Bristol Myers Squibb, 2seventy Bio Eyeing Earlier-Line Multiple Myeloma Abecma Indication
The companies plan to discuss with regulators interim data from the KarMMa-3 trial, in which multiple myeloma patients received the CAR T-cell therapy earlier.
OriCell Therapeutics Raises $120M in Series B Round
The Shanghai-based company will use the funds to advance its pipeline of CAR T-cell therapies and bispecific antibodies and to construct a manufacturing facility.Â
European Commission Approves Gilead Sciences' Yescarta for Follicular Lymphoma Patients
The autologous CAR T-cell therapy is now available in Europe as a fourth-line option for relapsed or refractory follicular lymphoma patients.
EMA's CHMP Recommends Novartis' Scemblix for TKI-Intolerant Chronic Myeloid Leukemia Patients
The committee recommended the STAMP inhibitor for previously treated Philadelphia chromosome-positive CML patients based on data from the ASCEMBL trial.
The agency acknowledges its staff can't keep up with the volume of cell and gene therapy products and is looking to PDUFA VII for additional funds.Â